Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3705)
All Articles published online
|
May 7, 2009 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3214/full/v15/i17/2067.htm |
| Number | Citing Articles |
| 1 |
Maria Rojas-Feria, Mohammed Eslam, Manuel Castro-Fernández, Pedro Guerrero, Jose-Luis Larraona-Moreno, Manuel Romero-Gómez. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. Journal of Crohn's and Colitis 2011; 5(6): 608 doi: 10.1016/j.crohns.2011.04.015
|
| 2 |
Gert Van Assche, James D Lewis, Gary R Lichtenstein, Edward V Loftus, Qin Ouyang, Julian Panes, Corey A Siegel, William J Sandborn, Simon P L Travis, Jean-Frederic Colombel. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. American Journal of Gastroenterology 2011; 106(9): 1594 doi: 10.1038/ajg.2011.211
|
| 3 |
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis. Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. Intestinal Research 2021; 19(4): 461 doi: 10.5217/ir.2020.00042
|
| 4 |
Manuela Marzo, Carla Felice, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi. Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. Clinical Medicine Insights: Therapeutics 2011; 3: CMT.S1978 doi: 10.4137/CMT.S1978
|
| 5 |
Giovanni Casella, Vincenzo Villanacci, Camillo Di Bella, Elisabetta Antonelli, Vittorio Baldini, Gabrio Bassotti. Pulmonary diseases associated with inflammatory bowel diseases. Journal of Crohn's and Colitis 2010; 4(4): 384 doi: 10.1016/j.crohns.2010.02.005
|
| 6 |
Carissa M. Thomas, Delphine M. A. Saulnier, Jennifer K. Spinler, Peera Hemarajata, Chunxu Gao, Sara E. Jones, Ashley Grimm, Miriam A. Balderas, Matthew D. Burstein, Christina Morra, Daniel Roeth, Markus Kalkum, James Versalovic. FolC2‐mediated folate metabolism contributes to suppression of inflammation by probiotic Lactobacillus reuteri. MicrobiologyOpen 2016; 5(5): 802 doi: 10.1002/mbo3.371
|
| 7 |
Tolga Sursal, Deborah J. Stearns-Kurosawa, Kiyoshi Itagaki, Sun-Young Oh, Shiqin Sun, Shinichiro Kurosawa, Carl J. Hauser. Plasma Bacterial and Mitochondrial DNA Distinguish Bacterial Sepsis From Sterile Systemic Inflammatory Response Syndrome and Quantify Inflammatory Tissue Injury in Nonhuman Primates. Shock 2013; 39(1): 55 doi: 10.1097/SHK.0b013e318276f4ca
|
| 8 |
Isabelle Cleynen, Séverine Vermeire. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nature Reviews Gastroenterology & Hepatology 2012; 9(9): 496 doi: 10.1038/nrgastro.2012.125
|
| 9 |
Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Jarosław Chmielnicki, Rafał Filip, Anna Pękala, Maria Janiak, Krzysztof Skrobot, Ewa Kasińska, Michał Krogulecki, Piotr Królikowski, Maria Kłopocka, Ariel Liebert, Elżbieta Poniewierka, Izabela Smoła, Anita Gąsiorowska, Aleksandra Kaczka, Joanna Wypych, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therapeutic Advances in Gastroenterology 2021; 14: 175628482110364 doi: 10.1177/17562848211036456
|
| 10 |
J. Présumey, G. Salzano, G. Courties, M. Shires, F. Ponchel, C. Jorgensen, F. Apparailly, G. De Rosa. PLGA microspheres encapsulating siRNA anti-TNFalpha: Efficient RNAi-mediated treatment of arthritic joints. European Journal of Pharmaceutics and Biopharmaceutics 2012; 82(3): 457 doi: 10.1016/j.ejpb.2012.07.021
|
| 11 |
Bo Qiu, Jia-Xu Liang, Cong Li. Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Medicine 2022; 101(40): e30590 doi: 10.1097/MD.0000000000030590
|
| 12 |
Marianna Carone, Marianne R. Spalinger, Robert A. Gaultney, Raffaele Mezzenga, Kristýna Hlavačková, Aart Mookhoek, Philippe Krebs, Gerhard Rogler, Paola Luciani, Simone Aleandri. Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis. Nature Communications 2023; 14(1) doi: 10.1038/s41467-023-39013-3
|
| 13 |
Xue-Liang Jiang, Hui-Fei Cui, Jing Gao, Hua Fan. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. Journal of Clinical Gastroenterology 2015; 49(7): 582 doi: 10.1097/MCG.0000000000000319
|
| 14 |
Abhik Bhattacharya, Daniel Travis, Mark T. Osterman, James D. Lewis, Bhavana Bhagya Rao, Helen Lee, Gary R. Lichtenstein. Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn’s Disease. Journal of Clinical Gastroenterology 2023; 57(1): 66 doi: 10.1097/MCG.0000000000001637
|
| 15 |
Xiao-Qing Ji, Li-Xia Wang, De-Gan Lu. Pulmonary manifestations of inflammatory bowel disease. World Journal of Gastroenterology 2014; 20(37): 13501-13511 doi: 10.3748/wjg.v20.i37.13501
|
| 16 |
Z. Arora, B. Shen. Biological therapy for ulcerative colitis. Gastroenterology Report 2015; 3(2): 103 doi: 10.1093/gastro/gou070
|
| 17 |
A. W. G. Waugh, S. Garg, K. Matic, L. Gramlich, C. Wong, D. C. Sadowski, M. Millan, R. Bailey, D. Todoruk, R. Cherry, C. W. Teshima, L. Dieleman, R. N. Fedorak. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort. Alimentary Pharmacology & Therapeutics 2010; 32(9): 1129 doi: 10.1111/j.1365-2036.2010.04446.x
|
| 18 |
Muhammad Abaidullah, Shaokai La, Mengqi Liu, Boshuai Liu, Yalei Cui, Zhichang Wang, Hao Sun, Sen Ma, Yinghua Shi. Polysaccharide from Smilax glabra Roxb Mitigates Intestinal Mucosal Damage by Therapeutically Restoring the Interactions between Gut Microbiota and Innate Immune Functions. Nutrients 2023; 15(19): 4102 doi: 10.3390/nu15194102
|
| 19 |
Jeff Chang, Rupert WL Leong. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2014; 14(1): 27 doi: 10.1517/14712598.2014.853738
|
| 20 |
Shivaram Bhat, Divyesh Sharma, Pauline Doherty, Tony C.K. Tham, Grant R. Caddy. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?. Inflammatory Bowel Diseases 2010; 16(11): 1922 doi: 10.1002/ibd.21279
|
| 21 |
Bo Xiao, Qiubing Chen, Zhan Zhang, Lixin Wang, Yuejun Kang, Timothy Denning, Didier Merlin. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis. Journal of Controlled Release 2018; 287: 235 doi: 10.1016/j.jconrel.2018.08.021
|
| 22 |
Ye Liu, Jinjian Huang, Sicheng Li, Ze Li, Canwen Chen, Guiwen Qu, Kang Chen, Yitian Teng, Rui Ma, Xiuwen Wu, Jianan Ren. Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review. Biomaterials Science 2024; 12(4): 837 doi: 10.1039/D3BM01645E
|
| 23 |
Ernst Beinder, Thorsten Fischer, Dieter Grab, Thomas Grubert, Peer Hantschmann, Franz Kainer, Ralph Kästner, Christina Kentenich, Walter Klockenbusch, Reinhard Kopp, Frank Lammert, Frank Louwen, Ioannis Mylonas, Stephanie Pildner von Steinburg, Werner Rath, Ute M. Schäfer-Graf, Ekkehard Schleußner, Ralf Schmitz, Maximilian Sohn, Heinrich Otto Steitz. Facharzt Geburtsmedizin. 2012; : 369 doi: 10.1016/B978-3-437-23751-5.10017-2
|
| 24 |
Xiang Xue, Sadeesh Ramakrishnan, Erik Anderson, Matthew Taylor, Ellen M. Zimmermann, Jason R. Spence, Sha Huang, Joel K. Greenson, Yatrik M. Shah. Endothelial PAS Domain Protein 1 Activates the Inflammatory Response in the Intestinal Epithelium to Promote Colitis in Mice. Gastroenterology 2013; 145(4): 831 doi: 10.1053/j.gastro.2013.07.010
|
| 25 |
Sherman Picardo, Kenji So, Kannan Venugopal. Anti‐TNF‐induced lupus in patients with inflammatory bowel disease. JGH Open 2020; 4(3): 507 doi: 10.1002/jgh3.12291
|
| 26 |
N Plevris, C S Chuah, R M Allen, I D Arnott, P N Brennan, S Chaudhary, A M D Churchhouse, S Din, E Donoghue, D R Gaya, M Groome, H M Jafferbhoy, P W Jenkinson, W L Lam, M Lyons, J C Macdonald, M MacMaster, C Mowat, G D Naismith, L F Potts, E Saffouri, J P Seenan, A Sengupta, P Shasi, D I Sutherland, J A Todd, J Veryan, A J M Watson, D A Watts, G R Jones, C W Lees. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Journal of Crohn's and Colitis 2019; 13(9): 1111 doi: 10.1093/ecco-jcc/jjz042
|
| 27 |
Christina Kriegel, Mansoor M Amiji. Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease. Clinical and Translational Gastroenterology 2011; 2(3): e2 doi: 10.1038/ctg.2011.1
|
| 28 |
Jatinder P. Ahluwalia. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012; 96(3): 525 doi: 10.1016/j.mcna.2012.04.009
|
| 29 |
Ruixia Li, Xiaofei Li, He Zhou, Yanting Shi, Fang Wang, Tong Wu, Jie Liang. Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1205046
|
| 30 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2009; 18(12) doi: 10.1002/pds.1655
|
| 31 |
Ellen A. Lipstein, Maria T. Britto. Evolution of Pediatric Chronic Disease Treatment Decisions. Medical Decision Making 2015; 35(6): 703 doi: 10.1177/0272989X15581805
|
| 32 |
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J Sandborn. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry. American Journal of Gastroenterology 2012; 107(9): 1409 doi: 10.1038/ajg.2012.218
|
| 33 |
Victor Klimyuk, Gregory Pogue, Stefan Herz, John Butler, Hugh Haydon. Plant Viral Vectors. Current Topics in Microbiology and Immunology 2012; 375: 127 doi: 10.1007/82_2012_212
|
| 34 |
Raymond K. Cross. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. Inflammatory Bowel Diseases 2017; 23(10): 1689 doi: 10.1097/MIB.0000000000001261
|
| 35 |
Giorgia Bodini, Maria Giulia Demarzo, Margherita Saracco, Claudia Coppo, Costanza De Maria, Isabella Baldissarro, Edoardo Savarino, Vincenzo Savarino, Edoardo G. Giannini. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2019; 54(10): 1220 doi: 10.1080/00365521.2019.1666914
|
| 36 |
Sebastian Strobel, Maria T. Abreu. Biologic Therapy in Inflammatory Bowel Disease—A Gastrointestinal Perspective. Seminars in Colon and Rectal Surgery 2012; 23(2): 81 doi: 10.1053/j.scrs.2012.02.007
|
| 37 |
Silvio Danese, Kavitha Subramaniam, Jan Van Zyl, Shashi Adsul, Dirk Lindner, Jeannine Roth, Séverine Vermeire. Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme. Alimentary Pharmacology & Therapeutics 2021; 53(2): 265 doi: 10.1111/apt.16160
|
| 38 |
Husain Attarwala, Mansoor Amiji. Handbook of Polyester Drug Delivery Systems. 2016; : 417 doi: 10.1201/b20045-14
|
| 39 |
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Current Gastroenterology Reports 2020; 22(9) doi: 10.1007/s11894-020-00781-3
|
| 40 |
Dejun Cui, Guomei Huang, Daping Yang, Bo Huang, Bangquan An. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2013; 37(5): 507 doi: 10.1016/j.clinre.2012.12.004
|
| 41 |
Ellen A. Lipstein, Cassandra M. Dodds, Daniel J. Lovell, Lee A. Denson, Maria T. Britto. Making decisions about chronic disease treatment: a comparison of parents and their adolescent children. Health Expectations 2016; 19(3): 716 doi: 10.1111/hex.12210
|
| 42 |
Roberta Elisa Rossi, Ioanna Parisi, Edward John Despott, Andrew Kenneth Burroughs, James O'Beirne, Dario Conte, Mark Ian Hamilton, Charles Daniel Murray. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World Journal of Gastroenterology 2014; 20(46): 17352-17359 doi: 10.3748/wjg.v20.i46.17352
|
| 43 |
Min Kyoung Cho, Mi Kyung Park, Shin Ae Kang, Seon Hee Choi, Soon Cheol Ahn, Hak Sun Yu. Trichinella spiralis Infection Suppressed Gut Inflammation with CD4+CD25+Foxp3+T Cell Recruitment. The Korean Journal of Parasitology 2012; 50(4): 385 doi: 10.3347/kjp.2012.50.4.385
|
| 44 |
Steffen Dan‐Nielsen, Vibeke Wewer, Anders Paerregaard, Lars F. Hansen, Rasmus G. Nielsen, Aksel Lange, Christian Jakobsen. Does Infliximab Prevent Colectomy in Acute and Chronic Active Ulcerative Colitis?. Journal of Pediatric Gastroenterology and Nutrition 2014; 58(6): 768 doi: 10.1097/MPG.0000000000000340
|
| 45 |
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro, Gabriel Mezzano. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2022; 16(7): 1168 doi: 10.1093/ecco-jcc/jjac013
|
| 46 |
Laura Jansen, Xander G Vos, Mark Löwenberg. Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitis. World Journal of Clinical Cases 2016; 4(2): 60-62 doi: 10.12998/wjcc.v4.i2.60
|
| 47 |
Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuki Toyokawa, Makoto Tanaka, Yuma Hotta, Kazuhiro Kamada, Takeshi Ishikawa, Hideyuki Konishi, Mitsuo Kishimoto, Yuji Naito, Yoshito Itoh. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01709-5
|
| 48 |
Christina Kriegel, Mansoor Amiji. Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. Journal of Controlled Release 2011; 150(1): 77 doi: 10.1016/j.jconrel.2010.10.002
|
| 49 |
Tripti Khare, Sushesh Srivatsa Palakurthi, Brijesh M. Shah, Srinath Palakurthi, Sharad Khare. Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel Disease. International Journal of Molecular Sciences 2020; 21(11): 3956 doi: 10.3390/ijms21113956
|
| 50 |
Fanny Giron, Anna Pastó, Ennio Tasciotti, Bincy P Abraham. Nanotechnology in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; 25(12): 1871 doi: 10.1093/ibd/izz205
|
| 51 |
|
| 52 |
Sam C. Nalle, Jerrold R. Turner. Biology and Regulation of Blood-Tissue Barriers. Advances in Experimental Medicine and Biology 2013; 763: 105 doi: 10.1007/978-1-4614-4711-5_5
|
| 53 |
Honghui Zhou, Yan Xu, Amarnath Sharma. Pharmaceutical Biotechnology. 2019; : 557 doi: 10.1007/978-3-030-00710-2_26
|
| 54 |
Honghui Zhou, Zhenhua Xu, Mary Ann Mascelli, Hugh M. Davis. Pharmaceutical Biotechnology. 2013; : 393 doi: 10.1007/978-1-4614-6486-0_20
|
| 55 |
Husain Attarwala, Murui Han, Jonghan Kim, Mansoor Amiji. Oral nucleic acid therapy using multicompartmental delivery systems. WIREs Nanomedicine and Nanobiotechnology 2018; 10(2) doi: 10.1002/wnan.1478
|
| 56 |
Jeffrey B. Brown, Paul Cheresh, Zheng Zhang, Hyunji Ryu, Elizabeth Managlia, Terrence A. Barrett. P-Selectin Glycoprotein Ligand-1 Is Needed for Sequential Recruitment of T-Helper 1 (Th1) and Local Generation of Th17 T Cells in Dextran Sodium Sulfate (DSS) Colitis. Inflammatory Bowel Diseases 2012; 18(2): 323 doi: 10.1002/ibd.21779
|
| 57 |
Chunbai He, Lichen Yin, Yudong Song, Cui Tang, Chunhua Yin. Optimization of multifunctional chitosan–siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in rats. Acta Biomaterialia 2015; 17: 98 doi: 10.1016/j.actbio.2015.01.041
|
| 58 |
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Wayne Langholff, Anil Londhe, William J Sandborn. Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry. American Journal of Gastroenterology 2014; 109(2): 212 doi: 10.1038/ajg.2013.441
|
| 59 |
Kinga Majchrzak, Jakub Fichna. Biologic Therapy in Crohn’s Disease–What We Have Learnt So Far. Current Drug Targets 2020; 21(8): 792 doi: 10.2174/1389450121666191218123203
|
| 60 |
Koji Sono, Akihiro Yamada, Yasushi Yoshimatsu, Nobuo Takada, Yasuo Suzuki. Factors associated with the loss of response to infliximab in patients with Crohn’s disease. Cytokine 2012; 59(2): 410 doi: 10.1016/j.cyto.2012.04.026
|
| 61 |
Angelo V. Marzano, Alessandro Borghi, Pier Luigi Meroni, Carlo Crosti, Massimo Cugno. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014; 47(3): 146 doi: 10.3109/08916934.2013.873414
|
| 62 |
Palpandi Pandi, Anjali Jain, Saka Raju, Wahid Khan. Therapeutic approaches for the delivery ofTNF-αsiRNA. Therapeutic Delivery 2017; 8(5): 343 doi: 10.4155/tde-2017-0011
|
| 63 |
Sung Won Jang, Min Kyoung Cho, Mi Kyung Park, Shin Ae Kang, Byoung-Kuk Na, Soon Cheol Ahn, Dong-Hee Kim, Hak Sun Yu. Parasitic Helminth Cystatin Inhibits DSS-Induced Intestinal Inflammation Via IL-10+F4/80+Macrophage Recruitment. The Korean Journal of Parasitology 2011; 49(3): 245 doi: 10.3347/kjp.2011.49.3.245
|
| 64 |
Christina Kriegel, Husain Attarwala, Mansoor Amiji. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Advanced Drug Delivery Reviews 2013; 65(6): 891 doi: 10.1016/j.addr.2012.11.003
|
| 65 |
Ellen A. Lipstein, Daniel J. Lovell, Lee A. Denson, David W. Moser, Shehzad A. Saeed, Cassandra M. Dodds, Maria T. Britto. Parents' Information Needs in Tumor Necrosis Factor‐α Inhibitor Treatment Decisions. Journal of Pediatric Gastroenterology and Nutrition 2013; 56(3): 244 doi: 10.1097/MPG.0b013e31827496c3
|
| 66 |
H. Sales-Campos, P.J. Basso, V.B.F. Alves, M.T.C. Fonseca, G. Bonfá, V. Nardini, C.R.B. Cardoso. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research 2015; 48(2): 96 doi: 10.1590/1414-431x20143774
|
| 67 |
Annemay M. H. Stoker, Leslie Logghe, Mirjam C. M. van der Ende-van Loon, Erik J. Schoon, Ramon-Michel Schreuder, Arnold Stronkhorst, Lennard P. L. Gilissen. Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clinical and Experimental Medicine 2023; 23(6): 2789 doi: 10.1007/s10238-023-00994-6
|
| 68 |
Fernando Magro, Francisco Portela. Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies. BioDrugs 2010; 24: 3 doi: 10.2165/11586290-000000000-00000
|
| 69 |
Yan Xu, Jia Chen, Honghui Zhou. Pharmaceutical Biotechnology. 2024; : 591 doi: 10.1007/978-3-031-30023-3_24
|
| 70 |
Bernard Bizzini, Béatrice Drouet, Daniel Zagury, Marc Abitbol, Arsène Burny, Marie-Christophe Boissier. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy 2010; 2(3): 347 doi: 10.2217/imt.10.16
|
| 71 |
Laura Janssen, Mariëlle Romberg-Camps, Ad van Bodegraven, Jeoffrey Haans, Michèl Aquarius, Paul Boekema, Tamara Munnecom, Lloyd Brandts, Manuela Joore, Adrian Masclee, D Jonkers, M Pierik. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial. BMJ Open 2021; 11(5): e042885 doi: 10.1136/bmjopen-2020-042885
|
| 72 |
S. He, T. Li, H. Chen, W. Ma, Q. Yao, H. Yang, H. Wang, F. Wang, C. Zhao, P. Yang. CD14+ cell-derived IL-29 modulates proinflammatory cytokine production in patients with allergic airway inflammation. Allergy 2011; 66(2): 238 doi: 10.1111/j.1398-9995.2010.02455.x
|
| 73 |
Lucianna Motta Correia, Danielle Queiroz Bonilha, Juliana Dantas Ramos, Orlando Ambrogini, Sender Jankiel Miszputen. Treatment of inflammatory bowel disease and pregnancy: a review of the literature. Arquivos de Gastroenterologia 2010; 47(2): 197 doi: 10.1590/S0004-28032010000200016
|
| 74 |
Thomas W. Lee, Richard N. Fedorak. Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. Gastroenterology Clinics of North America 2010; 39(3): 543 doi: 10.1016/j.gtc.2010.08.018
|
| 75 |
Gregory P. Pogue, Fakhrieh Vojdani, Kenneth E. Palmer, Ernie Hiatt, Steve Hume, Jim Phelps, Lori Long, Natasha Bohorova, Do Kim, Michael Pauly, Jesus Velasco, Kevin Whaley, Larry Zeitlin, Stephen J. Garger, Earl White, Yun Bai, Hugh Haydon, Barry Bratcher. Production of pharmaceutical‐grade recombinant aprotinin and a monoclonal antibody product using plant‐based transient expression systems. Plant Biotechnology Journal 2010; 8(5): 638 doi: 10.1111/j.1467-7652.2009.00495.x
|
| 76 |
Isabel Nawroth, Jan Alsner, Mark A. Behlke, Flemming Besenbacher, Jens Overgaard, Kenneth A. Howard, Jørgen Kjems. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosis. Radiotherapy and Oncology 2010; 97(1): 143 doi: 10.1016/j.radonc.2010.09.010
|
| 77 |
Ryoki Takahashi, Takayasu Noguchi, Yoko Mizoguchi, Tadashi Shimoyama, Teruko Nakazawa, Tohru Ikuta. A Synbiotic with Tumor Necrosis Factor-αInhibitory Activity Ameliorates Experimental Jejunoileal Mucosal Injury. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/9184093
|
| 78 |
Cristhiane Favero de Aguiar, Angela Castoldi, Vinícius Andrade-Oliveira, Aline Ignacio, Flávia Franco da Cunha, Raphael José Ferreira Felizardo, Ênio José Bassi, Niels Olsen Saraiva Câmara, Danilo Candido de Almeida. Mesenchymal stromal cells modulate gut inflammation in experimental colitis. Inflammopharmacology 2018; 26(1): 251 doi: 10.1007/s10787-017-0404-6
|
| 79 |
Christine L. Schuler, Cassandra Dodds, Kevin A. Hommel, Richard F. Ittenbach, Lee A. Denson, Ellen A. Lipstein. Shared decision making in IBD: A novel approach to trial consent and timing. Contemporary Clinical Trials Communications 2019; 16: 100447 doi: 10.1016/j.conctc.2019.100447
|